

## Product datasheet for **TL310356**

### Plasminogen (PLG) Human shRNA Plasmid Kit (Locus ID 5340)

#### Product data:

|                           |   |
|---------------------------|---|
| Product Type:             | shRNA Plasmids  |
| Product Name:             | Plasminogen (PLG) Human shRNA Plasmid Kit (Locus ID 5340)   |
| Locus ID:                 | 5340  |
| Synonyms:                 | HAE4  |
| Vector:                   | pGFP-C-shLenti (TR30023)  |
| E. coli Selection:        | Chloramphenicol (34 ug/ml)  |
| Mammalian Cell Selection: | Puromycin   |
| Format:                   | Lentiviral plasmids   |
| Components:               | PLG - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 5340). 5µg purified plasmid DNA per construct<br>29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.  |
| RefSeq:                   | <a href="#">NM_000301</a> , <a href="#">NM_001168338</a> , <a href="#">NM_000301.1</a> , <a href="#">NM_000301.2</a> , <a href="#">NM_000301.3</a> , <a href="#">NM_001168338.1</a> , <a href="#">BC060513</a> , <a href="#">BC060513.1</a> , <a href="#">NM_000301.5</a> |
| UniProt ID:               | <a href="#">P00747</a>  |



[View online »](#)

|                                |   |
|--------------------------------|---|
| <b>Summary:</b>                | <p>The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflammation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020]</p> |
| <b>shRNA Design:</b>           | <p>These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a>.</p>   |
| <b>Performance Guaranteed:</b> | <p>OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.</p> <p>For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).</p>   |